335 related articles for article (PubMed ID: 16825091)
1. Long-term management of sevelamer hydrochloride-induced metabolic acidosis aggravation and hyperkalemia in hemodialysis patients.
Sonikian M; Metaxaki P; Iliopoulos A; Marioli S; Vlassopoulos D
Ren Fail; 2006; 28(5):411-8. PubMed ID: 16825091
[TBL] [Abstract][Full Text] [Related]
2. Sevelamer worsens metabolic acidosis in hemodialysis patients.
De Santo NG; Frangiosa A; Anastasio P; Marino A; Correale G; Perna A; Di Stazio E; Stellato D; Santoro D; Di Meglio E; Iacono G; Ciacci C; Savica V; Cirillo M
J Nephrol; 2006; 19 Suppl 9():S108-14. PubMed ID: 16736432
[TBL] [Abstract][Full Text] [Related]
3. Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated by sevelamer hydrochloride.
Sonikian MA; Pani IT; Iliopoulos AN; Koutala KG; Marioli SI; Vlassopoulos DA
Ren Fail; 2005; 27(2):143-7. PubMed ID: 15807177
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.
Wilkes BM; Reiner D; Kern M; Burke S
Clin Nephrol; 1998 Dec; 50(6):381-6. PubMed ID: 9877112
[TBL] [Abstract][Full Text] [Related]
5. Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage.
Oka Y; Miyazaki M; Takatsu S; Kunitomo K; Uno F; Maruyama M; Matsuda H
Ther Apher Dial; 2007 Apr; 11(2):107-13. PubMed ID: 17381531
[TBL] [Abstract][Full Text] [Related]
6. Is 2.5 mEq/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K/DOQI guidelines.
Izumi M; Shirai K; Ito K; Miyamoto T; Matsumoto A; Takenaka Y; Nakagawa K; Yamanashi T; Takamitsu Y; Nakanish T
Ther Apher Dial; 2005 Feb; 9(1):24-31. PubMed ID: 15828902
[TBL] [Abstract][Full Text] [Related]
7. Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients.
Filiopoulos V; Koutis I; Trompouki S; Hadjiyannakos D; Lazarou D; Vlassopoulos D
Ther Apher Dial; 2011 Feb; 15(1):20-7. PubMed ID: 21272248
[TBL] [Abstract][Full Text] [Related]
8. Acid-base profile and predictors of metabolic acidosis in patients undergoing peritoneal dialysis with lactate- and bicarbonate-buffered peritoneal dialysis solutions.
Fourtounas C; Savidaki E; Roumelioti M; Dousdampanis P; Hardalias A; Kalliakmani P; Papachristou E; Drakopoulos A; Goumenos DS; Vlachojannis JG
Adv Perit Dial; 2006; 22():187-91. PubMed ID: 16983967
[TBL] [Abstract][Full Text] [Related]
9. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
Pai AB; Shepler BM
Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
[TBL] [Abstract][Full Text] [Related]
10. Different routes bridging calcium in Japanese hemodialysis patients.
Hamano T; Fujii N; Ito T; Imai E
Ther Apher Dial; 2005 Feb; 9(1):32-8. PubMed ID: 15828903
[TBL] [Abstract][Full Text] [Related]
11. Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.
Kokuho T; Toya Y; Kawaguchi Y; Tamura K; Iwatsubo K; Dobashi Y; Nakazawa A; Takeda H; Iwatsubo M; Hirawa N; Yasuda G; Ohnishi T; Umemura S
Ther Apher Dial; 2007 Dec; 11(6):442-8. PubMed ID: 18028171
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal dialysis patients using sevelamer do not present the acidosis problems that hemodialysis patients do.
Pagé D; Knoll G
Adv Perit Dial; 2005; 21():185-7. PubMed ID: 16686315
[TBL] [Abstract][Full Text] [Related]
13. Sevelamer hydrochloride dose-dependent increase in prevalence of severe acidosis in hemodialysis patients: analysis of nationwide statistical survey in Japan.
Oka Y; Miyazaki M; Matsuda H; Takatsu S; Katsube R; Mori T; Takehara K; Umeda Y; Uno F
Ther Apher Dial; 2014 Feb; 18(1):37-43. PubMed ID: 24499082
[TBL] [Abstract][Full Text] [Related]
14. Direct effect of the correction of acidosis on plasma parathyroid hormone concentrations, calcium and phosphate in hemodialysis patients: a prospective study.
Movilli E; Zani R; Carli O; Sangalli L; Pola A; Camerini C; Scolari F; Cancarini GC; Maiorca R
Nephron; 2001 Mar; 87(3):257-62. PubMed ID: 11287761
[TBL] [Abstract][Full Text] [Related]
15. Chronic acid-base perturbations in hemodialysis patients treated with sevelamer hydrochloride: a two-year follow-up study.
Vlahakos DV; Retsa K; Kalogeropoulou S; Katsoudas S; Bacharaki D; Agroyannis B
Artif Organs; 2007 Dec; 31(12):892-5. PubMed ID: 17924988
[TBL] [Abstract][Full Text] [Related]
16. Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients on sevelamer hydrochloride: which dialysate calcium concentration to use?
Sonikian M; Metaxaki P; Karatzas I; Vlassopoulos D
Blood Purif; 2009; 27(2):182-6. PubMed ID: 19141997
[TBL] [Abstract][Full Text] [Related]
17. Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients.
Inoue T; Nagatoya K; Kagitani M; Shibahara N; Ueda H; Katsuoka Y; Ohashi S; Kitagawa Y; Nishimoto K; Yasuda H;
Ther Apher Dial; 2007 Jun; 11(3):210-4. PubMed ID: 17498003
[TBL] [Abstract][Full Text] [Related]
18. Calcium exposure and removal in chronic hemodialysis patients.
Sigrist M; McIntyre CW
J Ren Nutr; 2006 Jan; 16(1):41-6. PubMed ID: 16414440
[TBL] [Abstract][Full Text] [Related]
19. Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines.
Nolan CR
Kidney Int Suppl; 2005 Jul; (96):S7-14. PubMed ID: 15954948
[TBL] [Abstract][Full Text] [Related]
20. Long-term effect of different dialysate calcium concentrations on parathyroid hormone levels in hemodialysis patients.
Hwang JC; Chen CA; Wang CT; Chen HC
Ren Fail; 2008; 30(10):943-51. PubMed ID: 19016144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
